Professor | Guojun Zhang | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Guojun Zhang
Contact Information	gjzhang@xah.xmu.edu.cn
Language ability	Chinese, Japanese, English
Province	Fujian

Upload Avatar (500 x 500)

Name

Guojun Zhang

Contact Information

gjzhang@xah.xmu.edu.cn

Language ability

Chinese, Japanese, English

Province

Fujian

University/Lab Affiliation and Title	Xiamen University
Faculty	Medical
Academic Background & Achievements	1995.04~1999.03 Doctor of Surgery: Fukushima Medical University, Japan 1990.09~1995.12 Doctor of Medicine: China Medical University 1981.09~1987.07 Bachelor of Medicine: China Medical University, Japanese Medicine
Work Experience	2017~Present - Xiamen University Affiliated Xiang'an Hospital - Executive Dean, Director of Oncology Diagnosis and Treatment Center 2008~2017 - Shantou University Medical College Affiliated Cancer Hospital - Dean, Director of Breast Center 2005~2008 - Merck & Co. - Senior Scientist 1999~2004 - Harvard Medical School Dana-Farber Cancer Institute - Postdoctoral Researcher 1987~1993 - China Medical University First Affiliated Hospital - Resident Physician, Attending Physician, Lecturer
Awards	2011: Distinguished Professor of the Changjiang Scholars Program 2016: National Special Support Program for High-Level Talents 2013: Government Special Allowance Certificate by the State Council 2009: National Candidate of the New Century Talents Project 2021: Fujian Province High-Level Talent Introduction A Category 2020: Fujian Province High-Level Innovative Talent Introduction 2018: Fujian Province Leading Talent in Universities 2016: Guangdong Special Support Program for Outstanding Talents 2020: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award 2019: Second Prize of the Liaoning Province Science and Technology Progress Award 2017: Third Prize of the Guangdong Province Science and Technology Award 2020: Second Prize of the Xiamen City Science and Technology Progress Award 2019: Xiamen City High-Level Talent Introduction 'Double Hundred Plan' 2018: Xiamen City High-Level Health Leading Talent

University/Lab Affiliation and Title

Xiamen University

Faculty

Medical

Academic Background & Achievements

1995.04~1999.03 Doctor of Surgery: Fukushima Medical University, Japan
1990.09~1995.12 Doctor of Medicine: China Medical University
1981.09~1987.07 Bachelor of Medicine: China Medical University, Japanese Medicine

Work Experience

2017~Present - Xiamen University Affiliated Xiang'an Hospital - Executive Dean, Director of Oncology Diagnosis and Treatment Center
2008~2017 - Shantou University Medical College Affiliated Cancer Hospital - Dean, Director of Breast Center
2005~2008 - Merck & Co. - Senior Scientist
1999~2004 - Harvard Medical School Dana-Farber Cancer Institute - Postdoctoral Researcher
1987~1993 - China Medical University First Affiliated Hospital - Resident Physician, Attending Physician, Lecturer

Awards

2011: Distinguished Professor of the Changjiang Scholars Program
2016: National Special Support Program for High-Level Talents
2013: Government Special Allowance Certificate by the State Council
2009: National Candidate of the New Century Talents Project
2021: Fujian Province High-Level Talent Introduction A Category
2020: Fujian Province High-Level Innovative Talent Introduction
2018: Fujian Province Leading Talent in Universities
2016: Guangdong Special Support Program for Outstanding Talents
2020: Second Prize of the Chinese Anti-Cancer Association Science and Technology Award
2019: Second Prize of the Liaoning Province Science and Technology Progress Award
2017: Third Prize of the Guangdong Province Science and Technology Award
2020: Second Prize of the Xiamen City Science and Technology Progress Award
2019: Xiamen City High-Level Talent Introduction 'Double Hundred Plan'
2018: Xiamen City High-Level Health Leading Talent

Areas of Focus	Basic research on breast cancer Clinical translational research on molecular imaging and precise tumor treatment Research on intelligent medicine and multidisciplinary comprehensive diagnosis and treatment of tumors
Publications	Bioluminescent imaging of CDK2 inhibition in vivo, Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Shapiro G, Zhelev N, Kaelin Jr WG, 2004 Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways, Zhang GJ, Chen TB, Hargreaves R, Sur C, Williams Jr DL, 2008 Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy, Yang RQ, Wang PY, Lou KL, Dang YY, Tian HN, Li Y, Gao YY, Huang WH, Zhang YQ, Liu XL, Zhang GJ, 2022 RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery, Liu JJ, Wang Z, Nie LM, Zhu YY, Li G, Lin LL, Chen M, Zhang GJ, 2022 The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition in vivo, Guo CP, Guo YX, Liu JJ, Gao YY, Wei M, Zhao RJ, Chen M, Zhang GJ, 2021 Surgical Navigation for Malignancies Guided by Near-Infrared-II Fluorescence Imaging, Yang RQ, Lou KL, Wang PY, Gao YY, Zhang YQ, Chen M, Huang WH, Zhang GJ, 2021 MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines, Liang YK, Lin HY, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, Qi YZ, Kruyt FAE, Zhang GJ, 2018 Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers, Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB et al., 2018 Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals, He KS, Chi CW, Kou DQ, Huang WH, Wu JD, Wang YB, He LF, Ye JZ, Mao YM, Zhang GJ, Wang JD, Tian J, 2016 Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels, Zhang GJ, Kimijima I, Fukushima T, Sato H, Kanno M, Tsuchiya A, Abe R, 1999

Areas of Focus

Basic research on breast cancer
Clinical translational research on molecular imaging and precise tumor treatment
Research on intelligent medicine and multidisciplinary comprehensive diagnosis and treatment of tumors

Publications

Bioluminescent imaging of CDK2 inhibition in vivo, Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Shapiro G, Zhelev N, Kaelin Jr WG, 2004
Bioluminescence imaging of hollow fibers in living animals: its application in monitoring molecular pathways, Zhang GJ, Chen TB, Hargreaves R, Sur C, Williams Jr DL, 2008
Biodegradable Nanoprobe for NIR-II Fluorescence Image-Guided Surgery and Enhanced Breast Cancer Radiotherapy Efficacy, Yang RQ, Wang PY, Lou KL, Dang YY, Tian HN, Li Y, Gao YY, Huang WH, Zhang YQ, Liu XL, Zhang GJ, 2022
RGD-functionalised melanin nanoparticles for intraoperative photoacoustic imaging-guided breast cancer surgery, Liu JJ, Wang Z, Nie LM, Zhu YY, Li G, Lin LL, Chen M, Zhang GJ, 2022
The G1 phase optical reporter serves as a sensor of CDK4/6 inhibition in vivo, Guo CP, Guo YX, Liu JJ, Gao YY, Wei M, Zhao RJ, Chen M, Zhang GJ, 2021
Surgical Navigation for Malignancies Guided by Near-Infrared-II Fluorescence Imaging, Yang RQ, Lou KL, Wang PY, Gao YY, Zhang YQ, Chen M, Huang WH, Zhang GJ, 2021
MiR-221/222 promote epithelial-mesenchymal transition by targeting Notch3 in breast cancer cell lines, Liang YK, Lin HY, Dou XW, Chen M, Wei XL, Zhang YQ, Wu Y, Chen CF, Bai JW, Xiao YS, Qi YZ, Kruyt FAE, Zhang GJ, 2018
Implementation and benchmarking of a novel analytical framework to clinically evaluate tumor-specific fluorescent tracers, Koller M, Qiu SQ, Linssen MD, Jansen L, Kelder W, de Vries J, Kruithof I, Zhang GJ, Robinson DJ, Nagengast WB et al., 2018
Comparison between the indocyanine green fluorescence and blue dye methods for sentinel lymph node biopsy using novel fluorescence image-guided resection equipment in different types of hospitals, He KS, Chi CW, Kou DQ, Huang WH, Wu JD, Wang YB, He LF, Ye JZ, Mao YM, Zhang GJ, Wang JD, Tian J, 2016
Tamoxifen-induced apoptosis in breast cancer cells relates to down-regulation of bcl-2, but not bax and bcl-XL, without alteration of p53 protein levels, Zhang GJ, Kimijima I, Fukushima T, Sato H, Kanno M, Tsuchiya A, Abe R, 1999

Breast Cancer Molecular Imaging Precision Surgery Tumor Navigation Oncology Translational Research Intelligent Medicine Multidisciplinary Treatment Cancer Metastasis Surgical Innovation

Chenfang Dong - Zhejiang University

Yiding Chen - Zhejiang University

Chao Ni - Zhejiang University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us